Cargando…

Presentation, treatment, and outcome of renovascular hypertension below 2 years of age

Renovascular hypertension in most cases requires endovascular treatment and/or surgery. This is technically much more difficult in small children and there is very limited published knowledge in this age group. We here present treatment and outcome of young children with renovascular hypertension at...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurt-Sukur, Eda Didem, Brennan, Eileen, Davis, Meryl, Forman, Colin, Hamilton, George, Kessaris, Nicos, Marks, Stephen D., McLaren, Clare A., Minhas, Kishore, Patel, Premal A., Roebuck, Derek J., Stojanovic, Jelena, Stuart, Sam, Tullus, Kjell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395438/
https://www.ncbi.nlm.nih.gov/pubmed/35792951
http://dx.doi.org/10.1007/s00431-022-04550-4
_version_ 1784771694134558720
author Kurt-Sukur, Eda Didem
Brennan, Eileen
Davis, Meryl
Forman, Colin
Hamilton, George
Kessaris, Nicos
Marks, Stephen D.
McLaren, Clare A.
Minhas, Kishore
Patel, Premal A.
Roebuck, Derek J.
Stojanovic, Jelena
Stuart, Sam
Tullus, Kjell
author_facet Kurt-Sukur, Eda Didem
Brennan, Eileen
Davis, Meryl
Forman, Colin
Hamilton, George
Kessaris, Nicos
Marks, Stephen D.
McLaren, Clare A.
Minhas, Kishore
Patel, Premal A.
Roebuck, Derek J.
Stojanovic, Jelena
Stuart, Sam
Tullus, Kjell
author_sort Kurt-Sukur, Eda Didem
collection PubMed
description Renovascular hypertension in most cases requires endovascular treatment and/or surgery. This is technically much more difficult in small children and there is very limited published knowledge in this age group. We here present treatment and outcome of young children with renovascular hypertension at our institution. Children below 2 years of age, with renovascular hypertension between January 1998 and March 2020 were retrospectively reviewed. Demographics and treatment modalities were noted. Primary outcome was blood pressure within a week after the procedures and at last available visit. Sixty-six angiographies were performed in 34 patients. Median age at time of first angiography was 1.03 (interquartile range (IQR) 0.4–1.4) years and systolic blood pressure at presentation 130 (IQR 130–150) mm Hg. Thirty-eight percent (13/34) of children were incidentally diagnosed and 18% (6/34) presented with heart failure. Twenty-six (76%) children had main renal artery stenosis and 17 (50%) mid-aortic syndrome. Seventeen (50%) children showed intrarenal, six (18%) mesenteric, and three (9%) cerebrovascular involvement. Twenty patients underwent 45 percutaneous transluminal angioplasty procedures and seven children surgeries. In 44% of the 16 patients who underwent only percutaneous transluminal angioplasty blood pressure was normalized, 38% had improvement on same or decreased treatment and 19% showed no improvement. Complications were seen in 7.5% (5/66) of angiographies. In four of the seven (57%) children who underwent surgery blood pressure was normalized, two had improved (29%) and one unchanged (14%) blood pressure. Conclusion: In small children with renovascular hypertension below the age of 2 years, percutaneous transluminal angioplasty caused significant improvement in blood pressure with low complication profile. Surgery can be recommended where percutaneous transluminal angioplasty and medical treatments failed.
format Online
Article
Text
id pubmed-9395438
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93954382022-08-24 Presentation, treatment, and outcome of renovascular hypertension below 2 years of age Kurt-Sukur, Eda Didem Brennan, Eileen Davis, Meryl Forman, Colin Hamilton, George Kessaris, Nicos Marks, Stephen D. McLaren, Clare A. Minhas, Kishore Patel, Premal A. Roebuck, Derek J. Stojanovic, Jelena Stuart, Sam Tullus, Kjell Eur J Pediatr Original Article Renovascular hypertension in most cases requires endovascular treatment and/or surgery. This is technically much more difficult in small children and there is very limited published knowledge in this age group. We here present treatment and outcome of young children with renovascular hypertension at our institution. Children below 2 years of age, with renovascular hypertension between January 1998 and March 2020 were retrospectively reviewed. Demographics and treatment modalities were noted. Primary outcome was blood pressure within a week after the procedures and at last available visit. Sixty-six angiographies were performed in 34 patients. Median age at time of first angiography was 1.03 (interquartile range (IQR) 0.4–1.4) years and systolic blood pressure at presentation 130 (IQR 130–150) mm Hg. Thirty-eight percent (13/34) of children were incidentally diagnosed and 18% (6/34) presented with heart failure. Twenty-six (76%) children had main renal artery stenosis and 17 (50%) mid-aortic syndrome. Seventeen (50%) children showed intrarenal, six (18%) mesenteric, and three (9%) cerebrovascular involvement. Twenty patients underwent 45 percutaneous transluminal angioplasty procedures and seven children surgeries. In 44% of the 16 patients who underwent only percutaneous transluminal angioplasty blood pressure was normalized, 38% had improvement on same or decreased treatment and 19% showed no improvement. Complications were seen in 7.5% (5/66) of angiographies. In four of the seven (57%) children who underwent surgery blood pressure was normalized, two had improved (29%) and one unchanged (14%) blood pressure. Conclusion: In small children with renovascular hypertension below the age of 2 years, percutaneous transluminal angioplasty caused significant improvement in blood pressure with low complication profile. Surgery can be recommended where percutaneous transluminal angioplasty and medical treatments failed. Springer Berlin Heidelberg 2022-07-06 2022 /pmc/articles/PMC9395438/ /pubmed/35792951 http://dx.doi.org/10.1007/s00431-022-04550-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kurt-Sukur, Eda Didem
Brennan, Eileen
Davis, Meryl
Forman, Colin
Hamilton, George
Kessaris, Nicos
Marks, Stephen D.
McLaren, Clare A.
Minhas, Kishore
Patel, Premal A.
Roebuck, Derek J.
Stojanovic, Jelena
Stuart, Sam
Tullus, Kjell
Presentation, treatment, and outcome of renovascular hypertension below 2 years of age
title Presentation, treatment, and outcome of renovascular hypertension below 2 years of age
title_full Presentation, treatment, and outcome of renovascular hypertension below 2 years of age
title_fullStr Presentation, treatment, and outcome of renovascular hypertension below 2 years of age
title_full_unstemmed Presentation, treatment, and outcome of renovascular hypertension below 2 years of age
title_short Presentation, treatment, and outcome of renovascular hypertension below 2 years of age
title_sort presentation, treatment, and outcome of renovascular hypertension below 2 years of age
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395438/
https://www.ncbi.nlm.nih.gov/pubmed/35792951
http://dx.doi.org/10.1007/s00431-022-04550-4
work_keys_str_mv AT kurtsukuredadidem presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT brennaneileen presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT davismeryl presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT formancolin presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT hamiltongeorge presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT kessarisnicos presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT marksstephend presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT mclarenclarea presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT minhaskishore presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT patelpremala presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT roebuckderekj presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT stojanovicjelena presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT stuartsam presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage
AT tulluskjell presentationtreatmentandoutcomeofrenovascularhypertensionbelow2yearsofage